ESR1 gene amplification in breast cancer: a common phenomenon?

[1]  Olivier Delattre,et al.  Two types of chromosome 1p losses with opposite significance in gliomas , 2005, Annals of neurology.

[2]  Emmanuel Barillot,et al.  Analysis of array CGH data: from signal ratio to gain and loss of DNA regions , 2004, Bioinform..

[3]  A. Vincent-Salomon,et al.  Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS * Study , 2003, Histopathology.

[4]  Emmanuel Barillot,et al.  BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas , 2007, International journal of cancer.

[5]  A. Vincent-Salomon,et al.  High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases , 2000, Histopathology.

[6]  O. Mariani,et al.  ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14–q15 and 6q23 amplifications , 2004, Genes, chromosomes & cancer.

[7]  G. Sauter,et al.  Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer , 2007, Nature Genetics.

[8]  A. Vincent-Salomon,et al.  Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity , 2007, Breast Cancer Research.

[9]  Emmanuel Barillot,et al.  Spatial normalization of array-CGH data , 2006, BMC Bioinformatics.

[10]  Céline Rouveirol,et al.  VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles , 2006, Bioinform..